| Literature DB >> 24658822 |
Giovanni F Torelli1, Nadia Peragine2, Sara Raponi2, Daria Pagliara3, Maria S De Propris2, Antonella Vitale2, Alice Bertaina3, Walter Barberi2, Lorenzo Moretta4, Giuseppe Basso5, Angela Santoni6, Anna Guarini2, Franco Locatelli7, Robin Foà2.
Abstract
In this study, we aimed to investigate the pathways of recognition of acute lymphoblastic leukemia blasts by natural killer cells and to verify whether differences in natural killer cell activating receptor ligand expression among groups defined by age of patients, or presence of cytogenetic/molecular aberrations correlate with the susceptibility to recognition and killing. We analyzed 103 newly diagnosed acute lymphoblastic leukemia patients: 46 adults and 57 children. Pediatric blasts showed a significantly higher expression of Nec-2 (P=0.03), ULBP-1 (P=0.01) and ULBP-3 (P=0.04) compared to adult cells. The differential expression of these ligands between adults and children was confined to B-lineage acute lymphoblastic leukemia with no known molecular alterations. Within molecularly defined subgroups of patients, a high surface expression of NKG2D and DNAM1 ligands was found on BCR-ABL(+) blasts, regardless of patient age. Accordingly, BCR-ABL(+) blasts proved to be significantly more susceptible to natural killer-dependent lysis than B-lineage blasts without molecular aberrations (P=0.03). Cytotoxic tests performed in the presence of neutralizing antibodies indicated a pathway of acute lymphoblastic leukemia cell recognition in the setting of the Nec-2/DNAM-1 interaction. These data provide a biological explanation of the different roles played by alloreactive natural killer cells in pediatric versus adult acute lymphoblastic leukemia and suggest that new natural killer-based strategies targeting specific subgroups of patients, particularly those BCR-ABL(+), are worth pursuing further. Copyright© Ferrata Storti Foundation.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24658822 PMCID: PMC4077088 DOI: 10.3324/haematol.2013.101931
Source DB: PubMed Journal: Haematologica ISSN: 0390-6078 Impact factor: 9.941